Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hematologic cancer
Biotech
IGM cuts head count 22%, stops blood cancer work to stretch cash
IGM revealed a 22% reduction in its head count and prioritization of its pipeline to make the hundreds of millions in its bank go further.
Nick Paul Taylor
Dec 6, 2023 10:11am
Caribou heads 'where the puck is going' with cell therapy plan
Jun 6, 2023 2:25pm
Precision to aim an off-the-shelf CAR-T at patients who relapse
May 31, 2023 10:58am
J&J, flush with blood cancer assets, cuts one from the pipeline
Oct 18, 2022 10:50am
Galecto links blood cancer prospect to reduced fibrosis
Sep 29, 2022 9:20am
ImmunoGen delays pivotal top-line blood cancer data to 2024
Aug 31, 2022 8:40am
